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Objectives: Human METCAM/MUC18 (huMETCAM/MUC18), a cell adhesion molecule, plays an important
role in the progression of several epithelial cancers; however, its role in the progression of epithelial
ovarian cancers is unknown. To initiate the study we determined expression of this protein in normal
and cancerous ovarian tissues, cystadenomas, metastatic lesions, and ovarian cancer cell lines.
Materials and methods: Immunoblotting and immunohistochemical (IHC) methods were used to deter-
mine huMETCAM/MUC18 expression in lysates of frozen and formalin-ﬁxed, parafﬁn-embedded tissue
sections of normal human ovaries, and ovarian (benign) cystadenomas, carcinomas and metastatic le-
sions. We also determined expression levels of several downstream effectors of METCAM/MUC18 in
these tissues.
Results: HuMETCAM/MUC18 levels in ovarian carcinomas and metastatic lesions were signiﬁcantly
higher than in normal tissues and cystadenomas. IHC results showed that expression of huMETCAM/
MUC18 in normal tissues and cystadenomas was mostly absent from epithelial cells, but in carcinomas
and metastatic lesions it was localized to epithelial cells. In higher pathological grades of ovarian cancer
and metastatic lesions, the percentage of cells stained in IHC was increased. Thirty percent of normal
tissues weakly expressed the huMETCAM/MUC18 antigen, but 70% of cancer tissues and 100% of met-
astatic lesions expressed the antigen. Expression levels of several downstream effectors of huMETCAM/
MUC18, Bcl2, PCNA and VEGF, were elevated in cancerous tissues, however, not that of Bax. The phospho-
AKT/AKT ratio was elevated in metastatic lesions.
Conclusion: Upexpression of huMETCAM/MUC18 may be a marker for the malignant potential of ovarian
carcinomas. Progression of ovarian cancer may involve increased signaling in anti-apoptosis, prolifera-
tion, survival/proliferation pathway, and angiogenesis.
Copyright © 2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Epithelial ovarian cancer is the ﬁfth most common cancer in
women in the United States [1], but it is the most common cause of
death from gynecological cancers in this country. Because the early
stage of the disease is mostly asymptomatic, diagnosis often occurs
after the cancer has already disseminated throughout thece Technology, Chung Yuan
2023, Taiwan.
gmail.com (G.-J. Wu).
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bstetrics & Gynecology. Publishedperitoneal cavity [2,3]. The disease can be treated successfully in
the early stages, but effective therapy for the advanced stages of the
disease is lacking. Currently, the only validated marker, CA125/
MUC16, is not useful for diagnosis or prognosis (because of its
variability and lack of correlation with the metastatic potential of
ovarian cancer) in spite of its presence in the serum of more than
80% of womenwith ovarian carcinoma [2]. Thus, themajor problem
for an effective early diagnosis is the lack of reliable diagnostic
markers during the cancer progression. Accurate diagnosis is
further complicated by the fact that epithelial ovarian carcinomas
(90% of the ovarian carcinoma cases) are histologically heteroge-
neous and lack speciﬁc markers for the ﬁve major histologicalby Elsevier Taiwan LLC. All rights reserved.
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carcinomas (20% of cases), mucinous carcinomas (10% of cases),
clear cell adenocarcinomas (5e10% of cases), and transitional cell
carcinomas/malignant Brenner tumors [3].
Aberrant expression of cell adhesion molecules (CAMs) affects
the motility and invasiveness of many tumor cells in vitro and
metastasis in vivo, because CAMs govern the social behaviors of
cells by affecting the adhesion status of cells and modulating cell
signaling [4]. The metastatic potential of a tumor cell, as docu-
mented in many carcinomas, is actually the consequence of a
complex participation of many over- and underexpressed CAMs [4].
Likewise, CAMs play a very important role in regulating ovarian
cancer migration and attachment to the omentum, pelvic perito-
neum, bowel serosa, diaphragm, liver serosa, para-aortic and pelvic
lymph nodes, and the establishment of metastatic lesions [5,6]. The
effects of altered expression of CAMs on the metastasis of ovarian
cancer cells has been studied in relation to mucins [7], integrins [8],
CD44 [9], L1CAM [10], E-cadherin [11], and claudin-3 [12]; how-
ever, that of humanMETCAM/MUC18 (huMETCAM/MUC18) has not
been investigated.
METCAM/MUC18 is a CAM in the immunoglobulin gene super
family [13,14]. The ectodomain of METCAM/MUC18 probably me-
diates the direct interactions with other cell types and the extra-
cellular matrix [13,14]. The cytoplasmic domain (64 amino acids) of
huMETCAM/MUC18 contains consensus sequences for ﬁve phos-
phorylation sites, one PKA, one casein kinase II (CK2), and three
protein kinase Cs (PKCs) [13,14]. The protein structure of huMET-
CAM/MUC18 suggests that it plays an active role in crosstalk with
many intracellular signaling pathways, thus impacting cellular
behaviors [13,14].
HuMETCAM/MUC18 is normally expressed in several tissues,
such as hair follicular cells, smooth muscle cells, endothelial cells,
cerebellum, normal mammary epithelial cells, basal cells of the
lung, intermediate trophoblast, and some activated T cells [15]. The
protein is frequently overexpressed in most (67%) malignant mel-
anoma cells [14] and in most (more than 80%) of the prostate
epithelial cells in PINs, high-grade prostatic carcinoma cells, and
metastatic lesions [16e19]. Furthermore, the effect of huMETCAM/
MUC18 expression on different tumor cells may vary; for example,
in melanoma huMETCAM/MUC18 has a minimal effect on tumori-
genesis, yet promotes the metastasis of melanoma cells, albeit at
the later stages [20e23]. In contrast, huMETCAM/MUC18 increases
tumorigenesis and initiates metastasis of human prostate cancer
LNCaP cells [24e26] and breast cancer cells [27e29]. Thus
huMETCAM/MUC18 is a bona ﬁdemetastatic gene for these cancers
[14]. In addition, more evidence seems to support the notion that
huMETCAM/MUC18 also plays an important role in promoting the
metastasis of other cancer types, such as angiosarcomas [14] and
osteosarcomas [30]. As a result, it is highly possible that huMET-
CAM/MUC18 may also play an important role in initiating the
metastasis of ovarian cancer cells, because it is well documented
that cancers from different tissues express some common cancer-
promoting genes in addition to tissue-speciﬁc genes [31].
To test the above hypothesis,weused immunologicalmethods to
determine the expression of huMETCAM/MUC18 in normal human
ovaries, cystadenomas, cancerous ovaries, andmetastatic lesions. In
this report, we show that huMETCAM/MUC18was overly expressed
in ovarian cancer and ovarian metastatic lesions compared to
normal ovarian and cystadenoma tissues, suggesting that the
overexpression of huMETCAM/MUC18 may be used as a diagnostic
marker for differentiating cancerous ovaries from normal ovaries
and from benign ovarian cysadenomas. We also determined the
expression levels of an apoptosis index (Bax), an anti-apoptosis
index (Bcl2), a proliferation index (proliferating cell nuclear anti-
gen [PCNA]), a survival and growth pathway index (phosphor-AKT/AKT), and an angiogenesis index (vascular endothelial growth factor
[VEGF]) in lysates of tumors and metastatic lesions. We show that
the levels of Bcl2, PCNA, and VEGF were elevated in lysates of tu-
mors, and the phospho-AKT/AKT ratio was elevated in metastatic
lesions, suggesting that these signaling pathways were involved in
the malignant progression of ovarian cancer.
Materials and methods
Ovarian tissues
Ovarian tissues were obtained from Northside Hospital given to
Ovarian Cancer Institute/Georgia Institute of Technology, Atlanta,
GA, and 5-mm sections of parafﬁn-embedded ovarian cancer tissues
were obtained from Emory University Hospital, Atlanta, GA. All
studies using human tissue were approved by institutional review
boards at both the Georgia Institute of Technology and Emory
University.
Growth of ovarian cancer cell lines
A SV40-T antigen immortalized human normal ovarian epithe-
lial cell line, IOSE [32] obtained from Dr Nelly Auersperg, Vancou-
ver, Canada, was maintained in M199/MCDB105 (1:1) medium
supplemented with 15% fetal bovine serum and 50 mg/mL of
gentamicin. The human ovarian cancer cell line BG-1 [33] (provided
by Dr Nathan Bowen, School of Biology, and the Ovarian Cancer
Institute, Georgia Institute of Technology) was maintained in
DMEM/F12 medium supplemented with 10% fetal bovine serum.
The human ovarian cancer cell line Hey [34] (provided by Dr Gor-
don Mills, Department of Molecular Therapeutics, MD Anderson
Cancer Center) was maintained in a modiﬁed RPMI 1640 medium
supplemented with 25mM HEPES buffer, 1mM sodium pyruvate,
1mM glutamine, 4.5% glucose, and 10% fetal bovine serum. Human
ovarian cancer cell lines, CAOV-3 and NIH:OVCAR-3 (or OVCAR3)
fromATCCweremaintained in DMEM supplementedwith 10% fetal
bovine serum and a modiﬁed RPMI 1640 medium supplemented
with 25mM HEPES buffer, 1mM sodium pyruvate, 1mM glutamine,
4.5% glucose, 20% fetal bovine serum 10 mg/mL of bovine insulin,
respectively. Human ovarian cell lines SK-OV-3 and CAOV-4 from
the American Type Culture Collection (ATCC), whichwere originally
established from ovarian metastatic lesions, were maintained in
McCoy's 5A medium supplemented with 10% fetal bovine serum
and Leibovitz's L-15 medium supplemented with 20% fetal bovine
serum, respectively. All the media were supplemented with peni-
cillin, streptomycin, and amphotericin B except the medium for the
IOSE cell line. The media were obtained from Invitrogen/Life
Technology/GIBCO/BRL or Cellgro/MediaTech, Carlsbad, CA, USA.
Fetal bovine serum was from Cellgro/MediaTech, Manassas, VA,
USA. All the cell lines were maintained in a 37C incubator with 5%
CO2, except CAOV-4, which was maintained in a 37C incubator
without CO2.
Immunoblot analysis
Lysates of ovarian tissues were prepared similarly to the pro-
cedures previously described [16e19,24,25]. The protein concen-
tration of each lysate was determined and veriﬁed by gel
electrophoresis and staining as described [16e19,24,25]. A
20e30 mg sample of protein from each tumor lysate was loaded in
each lane. The standard procedure of immunoblot analysis with
minormodiﬁcations was used [16e19,24,25]. The primary antibody
used for immunoblotting of METCAM/MUC18 protein was chicken
anti-huMETCAM/MUC18 IgY, which was obtained by immunizing
chickens with the puriﬁed middle portion of the recombinant
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[17e19,23e25]. The anti-huMETCAM/MUC18 polyclonal antibody
had a high speciﬁcity for recognizing the epitopes of huMETCAM/
MUC18 and a minimal cross-reactivity with the epitopes of mouse
METCAM/MUC18 [17e19,23e25].
In brief, after electrical blot the nitrocellulose membrane
(Hybond ECL, RPN3032D, GE Healthcare/Amersham) was blocked
with 5% nonfat milkeTris-buffered saline with Tween-20 (TBST)e
sodium azide at room temperature for 2 hours and reacted with 1/
200e1/300 dilution of a primary antibody (chicken anti-
huMETCAM/MUC18 IgY) in 5% nonfat milkeTBSTesodium azide
at 4C for 4e6 hours or overnight. The membrane was washed with
TBST, and reacted with 1/2000 dilution of a secondary antibody
(AP-conjugated rabbit ant chicken IgY antibody, AP162A, Chem-
icon) at room temperature for 1 hour. The membrane was washed
again with TBST, and reacted with NBT/BCIP for about 10e15 mi-
nutes, until the purple color of the protein band was fully devel-
oped. The image of the huMETCAM/MUC18 band from each
specimen was scanned with an Epson Photo Scanner model 1260
and its intensity was quantitatively determined by a NIH Image
J program version 1.31.
A dilution of 1/200 of the primary antibodies against human Bcl-
2 (N-19) (SC-492, rabbit polyclonal antibody, Santa Cruz Biotech),
Bax (N-20) (SC-493, rabbit polyclonal antibody, Santa Cruz Biotech),
anti-PCNA (C-20) (SC-9857, goat polyclonal antibody, Santa Cruz
Biotech), and anti- human VEGF (147) (SC-507, rabbit polyclonal
antibody, Santa Cruz Biotech) was used for the immunoblot ana-
lyses of the above proteins. A 1/2500 dilution of anti-pan-AKT
(AF2055, rabbit polyclonal antibody, R&D Systems, Inc.) and a
1/2000 dilution of anti-phospho (Ser473)-AKT antibody (AF-887,
rabbit polyclonal antibody, R&D Systems, Inc.) were used for the
immunoblot analyses of the AKT and phospho-AKT. Dilutions of the
corresponding AP-conjugated secondary antibodies, rabbit anti-
chicken IgY (AP162A, Chemicon), rabbit anti-goat (AP106 A,
Chemicon), rabbit anti-mouse (AP160A, Chemicon), or goat anti-
rabbit (AP132A, Chemicon) were all 1/2000. The color develop-
ment substrate BCIP/NBT (S3771, Promega) was used for the color
reaction for 30 minutes or overnight. The image of the speciﬁc
protein band on the membrane was scanned by the above scanner
and its intensity was quantitatively determined as described above.
All the data were statistically analyzed using the Student t test.
Histology and immunohistochemistry of ovarian tissue sections
Parafﬁn-embedded tissue sections (5 mm) were used. Tissue
sections were de-parafﬁnized, rehydrated, and used for histological
staining or immunohistochemical analyses [16e19,24,25]. For his-
tology, a standard procedure of staining with acidiﬁed Harris he-
matoxylin (#S212A, Poly Scientiﬁc, #245-677, Protocol, or
#23-245677, Fisher) and eosin philoxine (#S176, Poly Scientiﬁc), or
Eosin Y intensiﬁed solution (# 314-630, Protocol or #23-314-630,
Fisher), was used [25]. For the IHC with anti-huMETCAM/MUC18
antigens, sections of a human melanoma tissue and a tumor
derived from an LNCaP-expressing clone (LNS239) [25] were used
as positive external controls. Antigen-retrieval was carried out by
gentle boiling in a 20mM sodium citrate buffer (pH 6.0) at 95e97C
for 10 minutes and cooled for 60 minutes (temperature dropped
from 95C to about 37e42C) [16e19,24,25]. The endogenous
peroxidase was quenched with 3% hydrogen peroxide for 10 mi-
nutes. All tissue sections were blocked with 5% nonfat milk in TBST
with 0.02% sodium azide at room temperature for 2 hours and
followed at 4C for overnight, and reacted with the primary anti-
bodies (1/200e1/400 dilutions of the chicken anti-huMETCAM/
MUC18 IgY in 5% nonfat milk in TBST with and 0.02% sodium
azide) for 50 min at room temperature [25]. A secondary antibody(1/250 dilution of the biotin-conjugated rabbit anti-chicken IgY
antibodies, G2891, Promega, in freshlymade 5% nonfat milk in TBST
without sodium azide) was incubated for 30 minutes at room
temperature, a streptavidin-conjugated horseradish peroxidase
complex (K1016, Dako LSAAB-2 system) for 45 minutes, and dia-
minobenzidine as the chromogen for 20 minutes. The tissue sec-
tions were then counterstained with acidiﬁed Harris hematoxylin
(#245-677 Fisher) for 2 to 3 minutes. All the incubations were
performed at room temperature. Between incubations, sections
were washed three times with TBST. For negative controls, the
primary antibody was replaced by nonfat milk, chicken IgY, or anti-
mouse METCAM/MUC18 polyclonal antibodies (1/300 dilution). All
the tissues sections were dehydrated sequentially in increasing
concentrations of ethanol (50%, 70%, 80%, and 95%), followed by
three soakings in 100% ethanol, and three soakings in xylene.
Coverslips were mounted on the slides with a mounting medium
containing xylene-based synthetic resin (#S2153, Poly Scientiﬁc or
#245-690, Protocol or #23-245690, Fisher).
Statistical analysis
The calculation of standard deviations and the Student t test
(one-tail and type 2) in Microsoft Excel was used to analyze the
statistical signiﬁcance of the data in all ﬁgures. Two corresponding
sets of data were considered to be signiﬁcantly different if the p
value was <0.05.
Results
Expression of huMETCAM/MUC18 in ovarian tissues
Because huMETCAM/MUC18 promotes tumorigenesis and ini-
tiates metastasis of human breast and prostate cancer cells (cancers
of an epithelial cell origin) we sought to determine if huMETCAM/
MUC18 was also more highly expressed in epithelial ovarian cancer
and if the expressionwas associated with the clinical progression of
this disease. Using ONCOMINE, a public cancer microarray and
web-based data-mining platform (www.oncomine.org), we deter-
mined that the levels of expression of huMETCAM/MUC18 were
higher in neoplastic versus normal ovarian tissues (data not
shown). DNA microarray analysis of normal ovarian surface
epithelia (NOSE) and epithelial ovarian carcinoma (EOC) samples
from one of our laboratories indicated at least a 3-fold increase of
huMETCAM/MUC18 in EOC when compared to NOSE (data not
shown).
To follow up the results from the DNA microarray data, we used
immunoblotting techniques to determine the protein expression
levels of huMETCAM/MUC18 in several normal tissue, benign tissue,
cancerous tissue, and metastatic lesion specimens. Fig. 1 shows a
moderate expression of huMETCAM/MUC18 in normal ovarian tis-
sues, a high expression in all (100%) ovarian cancer tissues, and
moderate expression in all (100%) metastatic lesions; however, a
very weak expression of the protein in cystadenomas. The huMET-
CAM/MUC18 levels in normal ovarian tissues, cancerous ovarian
tissues, and metastatic lesions were 3.6 (p ¼ 0.02), 10.4 (p ¼ 0.007),
and 4 (p ¼ 0.0085) times that in cystadenomas, respectively
(Fig. 1B). Thus the expression level of the huMETCAM/MUC18 pro-
tein in cancerous ovarian tissues was 2.9-fold higher than that in
normal ovarian tissues and 10.4-fold higher than that in cys-
tadenomas. The expression level of the huMETCAM/MUC18 protein
in cancerous ovarian tissues was 2.6-fold higher than that in met-
astatic lesions. Furthermore, the apparent electrophoretic mobility
of huMETCAM/MUC18 expressed in ovarian tissues was similar to
that in a human melanoma cell line, SK-Mel-28, and human mela-
noma, prostate, breast cancer, and bladder cancer cell lines.
Fig. 1. Expression of huMETCAM/MUC18 protein in normal, benign, cancerous, and
ovarian metastatic lesions. (A) Results of immunoblot analyses of the ovarian tissues;
20 mg protein of each tumor lysate or cell line lysate was loaded per lane. The
expression of huMETCAM/MUC18 protein in a human melanoma cell line, SK-Mel-28,
was used as a positive control. Actin was used as the loading control. (B) Quantitative
results of the immunoblot analyses in (A). The expression level of huMETCAM/MUC18
protein in a human melanoma cell line, SK-Mel-28, was assumed to be 100%. The p
values were calculated by using the data of benign (cystadenomas), or normal ovarian
tissues, or cancerous tissues as the reference.
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expression of huMETCAM/MUC18 in different cell types, IHC of
parafﬁnized tissue sections of normal ovaries, ovarian cys-
tadenomas, ovarian cancers, and ovarian metastatic lesions was
carried out, as shown in Fig. 2A and that in different stages of
ovarian cancers, as shown in Fig. 3A. The antigen of huMETCAM/
MUC18 was expressed mostly in the smooth muscle cells and
vasculature in normal ovarian tissue sections and in cystadenomas,
as shown in Figs. 2A and 3A. In contrast, the huMETCAM/MUC18
antigen was expressed in a greater majority of cells and at higher
levels in most of the cancer tissue sections and metastatic lesions
(Figs. 2A and 3A). Note that the apparent levels of huMETCAM/
MUC18 analyzed by immunoblot analyses were lower in metastatic
lesions than in cancer tissues (Fig. 2A). The quantitative results of
IHC are shown in Fig. 2B, indicating that the percentage of cells
stained by the anti-huMETCAM/MUC18 antibody was higher in
both cancerous tissues (p ¼ 0.011) and metastatic lesions
(p ¼ 0.017) in comparison with normal tissues and cystadenomas.
Fig. 3A shows similar observations when tissue sections were from
different clinical stages and Fig. 3B shows that the percentage of
cells stained by the anti-huMETCAM/MUC18 antibody was at the
highest in the pathological Grade III cancers and in the metastatic
lesions in comparison with normal tissues and lower pathological
grades of ovarian cancer; however not much difference between
the pathological Grade III and metastatic lesions (p > 0.05). Table 1
summarizes the results of the IHC of the expression of huMETCAM/
MUC18 in these tissues, showing that huMETCAM/MUC18 was
expressed in about 85% of the ovarian cancer tissues and 100% of
ovarian metastatic lesions, but only 30% of normal ovarian tissues.
The METCAM/MUC18 antigens were also expressed in most
(83%) serous carcinomas (stage IIIC), one serous carcinoma with a
transitional differentiation, one mucinous carcinomawith a known
low malignant potential, one ovarian adenocarcinoma (Stage IC),
and one mixed type epithelial ovarian cancer (Stage IIIC). Theexpression of the METCAM/MUC18 antigen was signiﬁcantly
detectable in a low malignant potential serous ovarian cancer and
in adenocarcinoma. In contrast it was not expressed in one
mucinous adenocarcinoma and in one serous carcinoma (Stage
IIIA), but weakly expressed in 50% of the endometrioid carcinomas
(data not shown).
Expression of huMETCAM/MUC18 in various ovarian cancer cell
lines
The levels of huMETCAM/MUC18 expressed in various ovarian
cancer cell lines ranged a great deal, from 5 to 50%, when compared
to a positive control, the human melanoma cell line SK-MEL-28
(assuming to be 100%). SK-MEL-28 was used as a positive control
because it has the highest expression level of METCAM/MUC18
documented to date. One cell line, BG-1, did not express any
huMETCAM/MUC18 (Fig. 4 and Table 2). As summarized in Table 2,
the apparent average relative expression level of huMETCAM/
MUC18 in the cell lines derived from ovarian carcinomas was 25.6%,
about twice of that observed in cell lines derived from the malig-
nant ascites/metastases (13.3%), appearing to be similar to our
above observations for ovarian cancer tissues and ovarian meta-
static lesions. As also shown in Fig. 4, the apparent electrophoretic
mobility of huMETCAM/MUC18 expressed in ovarian cancer cell
lines was similar to that in a humanmelanoma cell line, SK-Mel-28,
and human melanoma, prostate, breast cancer, and bladder cancer
cell lines. Taken together of all the results, we were certain that
huMETCAM/MUC18 was expressed in the cell lines derived from
ovarian cancers and metastatic lesions, though the expression level
varied greatly in different cell lines.
Expression of various signaling parameters downstream of
huMETCAM/MUC18 in ovarian tissues
HuMETCAM/MUC18 has been shown to affect many important
downstream factors, such as proliferation, survival signaling,
angiogenesis, and apoptosis, which control tumorigenesis and
metastasis [14,35]. To understand the contribution of these key
signaling molecules in the processes of tumorigenesis and metas-
tasis of ovarian carcinomas, the levels of apoptosis indexes, PCNA,
phospho-AKT, and VEGF in the lysates made from frozen tissues of
normal ovary, benign cytadenomas, ovarian cancers, andmetastatic
lesions in ovaries were determined by immunoblot analyses using
speciﬁc antibodies. As shown in Fig. 5A, Bcl-2 levels were higher in
cancerous tissues than in the other kinds of tissue. In contrast, the
Bax level was similar in all four types of ovarian tissues, as shown in
Fig. 5B. The level of PCNA was signiﬁcantly higher (p < 0.01) in
cancerous tissues than in all other kinds of tissues; it was signiﬁ-
cantly higher inmetastatic lesions (p < 0.01) than in normal ovarian
tissues and cystadenomas, as shown in Fig. 6. The level of activated
AKT (phospho-AKT) was higher in metastatic lesions than in three
other kinds of tissues, as shown in Fig. 7. The level of the active form
of VEGF (21kDa) was slightly higher in cancerous tissues than in
other three kinds of tissues, as shown in Fig. 8.
Taken together, levels of Bcl-2, PCNA, and VEGF were signiﬁ-
cantly higher in cancerous tissues and phospho-AKT was signiﬁ-
cantly higher in metastatic lesions than in normal ovarian tissues
and benign cystadenomas.
Discussion
In this report, we showed from immunoblot results that the
expression level of the huMETCAM/MUC18 protein in cancerous
ovarian tissues was signiﬁcantly higher (2.9-fold) than that in
normal ovarian tissues, consistent with our DNA microarray
Fig. 2. Immunohistochemistry (IHC) of the expression of huMETCAM/MUC18 in normal, cystadenoma, ovarian cancer, and metastatic ovarian tissues. (Panel A) Results of IHC: (A,B)
shows representative examples of IHC for normal ovarian tissues, (C,D) cystadenomas, (EeG) ovarian cancers, and (HeL) metastatic lesions. Controls without the primary antibody
are shown in (A) and (C). (Panel B) Quantitative results of IHC in panel A. The average percentage of cells positively stained with the anti-huMETCAM/MUC18 antibody in ﬁve to 17
microscope ﬁelds was plotted against various ovarian tissues. The p values were calculated using the data of cystadenoma as the reference.
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in ovarian cancer tissues is about 3-fold higher than in normal
ovarian tissues. This suggests that elevated huMETCAM/MUC18
may be used for the clinical diagnosis of the emergence of ovarian
cancers. The expression level of the huMETCAM/MUC18 protein in
cancerous ovarian tissues was also signiﬁcantly higher than in
cystadenomas, suggesting that elevated huMETCAM/MUC18 may
also be used as a diagnostic biomarker in clinics to differentiate
ovarian cancers from benign cystadenomas.
To further conﬁrm the results of immunoblot analyses and to
establish the cell types that express huMETCAM/MUC18, we
showed in IHC that the expression of huMETCAM/MUC18 in normal
ovarian tissues and cystadenomas was mostly located in the
smooth muscle cells and vasculature, but not in epithelial cells. In
contrast, the expression of huMETCAM/MUC18 in the cancers and
metastatic lesions was mostly located in the ovarian epithelial cells.
This was further corroborated by the quantitative IHC results that
the expression level of huMETCAM/MUC18 antigen in ovariantissues was higher in cancerous tissues, metastatic lesions, and the
high pathological grade of ovarian cancers than in normal tissues
and lower grades of ovarian cancers.
We also noticed that the average huMETCAM/MUC18 level in
cell lines derived from primary tumors was about twice of that
found in ovarian carcinoma cell lines derived from metastatic le-
sions or ascites ﬂuid. This appeared to be consistent with the results
of immunoblot analysis that the expression level of huMETCAM/
MUC18 in ovarian cancerous tissues was 2.6-fold higher than in
metastatic lesions. However, this consistency may be somewhat
misleading, for several reasons. First, the expression levels between
two groups of cell lines was not statistically different; therefore the
2-fold difference of expression levels between the two groups of
cell lines was not considered meaningful. Second, immunoblot
analysis only detects the total expression level of a particular pro-
tein in a tissue lysate and does not differentiate between the
expression of a protein from one cell type to another. Because
huMETCAM/MUC18 is also expressed in the stromal cells, such as
Fig. 3. Immunohistochemistry (IHC) of huMETCAM/MUC18 expression in normal, different grades of ovarian cancerous and metastatic ovarian tissues. (Panel A) Results of IHC:
(A,B) shows the typical IHC of normal ovarian tissues, (C,D) Grade I ovarian cancers, (EeG) Grade II ovarian cancers, (HeJ) Grade III ovarian cancers, and (K,L) metastatic lesions.
(Panel B) Quantitative results of IHC in panel A. The average percentage of cells positively stained with the anti-huMETCAM/MUC18 antibody in ﬁve to 17 microscope ﬁelds was
plotted against normal and different grades of ovarian cancer. The p values were calculated by comparing the data from all different tissues to the data of Grade III ovarian cancer
tissues as the reference.
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epithelial cells may contribute to the total level of the total lysates
of cancerous tissues, whereas they do not contribute to the total
level of expression in metastatic lesions. Thus immunoblot analysisTable 1
HuMETCAM/MUC18 expression in the epithelium of the normal ovary, ovarian cancer, a
Histological/
pathological
classiﬁcation
Number of cases negative
for huMETCAM/MUC18
expression (%)
Number of cases positive
for huMETCAM/MUC18
expression (þ1)a (%)
Num
for h
exp
Normal ovary
(n ¼ 10)
7 (70) 3 (30) 0
Cancer (n ¼ 27)b 8 (30) 7 (26) 7 (2
Metastasis
(n ¼ 6)
0 1 (17) 1 (1
a The intensity and percentage of cells positive for the staining of huMETCAM/MUC18
b Twenty-seven ovarian cancer specimens include 17 serous adenocarcinoma, six endo
carcinomas.likely over-scored the contribution of METCAM/MUC18 expression
from epithelial cells in ovarian cancerous tissues to the total level.
This problem is resolved by the IHC analysis, which does differen-
tiate between the expressing METCAM/MUC18 from one cell typend metastatic lesions.
ber of cases positive
uMETCAM/MUC18
ression (þ2)a (%)
Number of cases positive
for huMETCAM/MUC18
expression (þ3)a (%)
Number of cases positive
for huMETCAM/MUC18
expression (%)
0 3/10 (30)
6) 5 (18) 19/27 (70)
7) 4 (66) 6/6 (100)
is deﬁned as: þ1, 5e10%; þ2, 20e30%; and þ3, 40e80%.
metrioid carcinomas, two mucinous carcinomas, and two mixed subtypes of ovarian
Fig. 4. Expression of huMETCAM/MUC18 in ovarian cancer cell lines versus a human
melanoma cell line (SK-Mel-28) and human prostate cancer cell lines (DU145, PC-3,
and LNCaP) and a human bladder cancer cell line (TSU-Pr1); 20 mg protein of each
cell line lysate was loaded per lane for immunoblot analysis. The top row shows the
expression of huMETCAM/MUC18 in a human melanoma cell line (SK-Mel-28 in lane1),
one human bladder cancer cell line (TSU-Pr1, lane 4), and three human prostate cancer
cell lines (DU145, PC-3, and LNCaP in lanes 2, 3 and 5, respectively), and six ovarian
cancer cell lines (IOSE, BG-1, HEY, CAOV3, SKOV3 and NIHOVCAR3 in lanes 6e11,
respectively). The middle and bottom rows show the expression of b-tubulin and actin,
respectively, as loading controls.
Fig. 5. Expression of (A) an antiapoptotic index (BCl-2) and (B) a proapoptotic index
(Bax) in ovarian tissues. The immunoblot analysis was carried out as described in the
Materials and methods section: 30 mg protein of each tumor lysate was loaded per lane.
The (A) Bcl2 (26 kDa) and (B) Bax (23 kDa) bands of the lysates of various ovarian
tissues on the membranes were scanned, and the intensity of each band was deter-
mined. All the p values in (A) were calculated with respect to the reference data in the
ovarian cancer tissues, as indicated by the asterisk. The p values in (B) was calculated
with respect to the reference data in benign ovarian tissues.
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cells stained by IHC in metastatic lesions was statistically as high as
that in cancerous tissues.
Taken together, huMETCAM/MUC18 was highly expressed in
both ovarian cancerous tissues and metastatic lesions, suggesting
that it may be an indicator for the malignant potential of ovarian
carcinomas. However, the positive correlation of the over-
expression of METCAM/MUC18with the advanced stages of ovarian
cancer andmetastatic lesions do not imply that METCAM/MUC18 is
directly involved in the progression of ovarian cancers, which re-
quires further testing the effect of METCAM/MUC18 on inducing
tumorigenesis and metastasis.
Previously, the expression of huMETCAM/MUC18 in ovarian
tissues had not been well studied because the mouse monoclonal
antibodies used by other groups did not recognize the epitopes of
the huMETCAM/MUC18 in ovarian tissues [15]. The positive resultsTable 2
The level of huMETCAM/MUC18 expression in various ovarian cell lines and tissues versus that in one human melanoma cell line and three human prostate cancer cell lines.
Cell line/tissue Cellular property Origin of tissues huMETCAM/MUC18
expression (%)
Tumor
formation
Metastatic
potential
IOSE Preneoplastic ovarian
epithelium
SV40-T antigen-immortalized ovarian epithelial cells 26 ± 2 None None
CAOV-3 Ovarian cancer cell line Human primary adenocarcinoma 50 ± 13 Yes None?
HEY Ovarian cancer cell line Xenografted human moderately differentiated
papillary cystadenocarcinoma
27 ± 3 Yes None?
BG-1 Ovarian cancer cell line Stage III human very poorly differentiated
adenocarcinoma
0 Yes None?
NIH:OVCAR3 Ovarian cancer cell line Human malignant ascites 15 ± 3 Yes, ascites Yes?
SK-OV-3 Ovarian cancer cell line Human adenocarcinoma metastasis as
malignant ascites
5 ± 2 Yes, ascites Yes
CAOV-4 Ovarian cancer cell line Human adenocarcinoma metastasis to
subserosa fallopian tube
20 Yes Yes
Human normal
ovarian
Normal ovarian tissue Human normal ovarian tissues 17.6 ± 9.5 None None
Human benign
ovarian adenoma
Benign ovarian Human benign ovarian tissues 4.86 ± 3.99 None None
Human ovarian
cancer
Ovarian cancer (serous) Human ovarian cancer 44.2 ± 28.4 Yes Yes
Human metastasis
lesion near ovaries
Metastatic lesions Human ovarian metastasis 17.78 ± 14.8 Yes Yes
SK-Mel-28 Melanoma cell line Human malignant melanoma 100 Yes Yes
DU145 Prostate cancer cell line Brain metastasis 44 ± 5 Yes Yes
PC-3 Prostate cancer cell line Bone metastasis 25 ± 5 Yes Yes
Tsu-PR1 Human bladder cancer 13 ± 2 Yes Yes?
LNCaP Prostate cancer cell line Lymph node metastasis 0 Yes None
Fig. 8. Expression of vascular endothelial growth factor (VEGF) in ovarian tissues. The
VEGF (21 kDa) bands of the lysates of various ovarian tissues (30 mg per lane) on the
membranes were scanned and the intensity of each band was determined.
Fig. 6. Expression of a proliferate index (proliferating cell nuclear antigen, PCNA) in
ovarian tissues. The PCNA (36 kDa) bands of the lysates of various ovarian tissues
(30 mg per lane) on the membranes were scanned and the intensity of each band were
determined. All the p values were calculated with respect to the reference data in the
benign ovarian tissues, as indicated by the asterisk.
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antibody, which recognizes multiple epitopes. In addition, the
chicken antibody used here has a higher speciﬁcity than mouse
monoclonal antibodies, as previously indicated [14,16,17,25e28].
To further investigate if the huMETCAM/MUC18 protein
expressed in ovarian cancer tissues was similar to that in human
ovarian cancer cell lines, we also used immunoblot analysis to
determine the size of the protein in several ovarian cell lines. We
showed that the apparent electrophoretic mobility of huMETCAM/
MUC18 expressed in ovarian cancer cell lines was similar to that in
ovarian tissues and that in a humanmelanoma cell line, SK-Mel-28,
and in human melanoma, prostate, breast cancer, and bladder
cancer cell lines. We suggest that post-translational modiﬁcations
such as glycosylation in the protein expressed in ovarian tissues
and ovarian cancer cell lines appear to be similar to that of other
human cancer cell lines.Fig. 7. Expression of a survival signal, ratio of phospho-AKT/AKT, in ovarian tissues.
The AKT (60 kDa) and phospho-AKT (S473) (60 kDa) of the lysates of various ovarian
tissues (30 mg per lane) on the membranes were scanned, and the intensity of each
band was determined. The ratio of phospho-AKT/AKT of each lysate was determined
and is shown. All the p values were calculated with respect to the expression values of
normal ovarian tissues, as indicated by the asterisk. The p values for each ovarian tissue
are indicated.HuMETCAM/MUC18 has been shown to increase the survival
ability of prostate cancer cells by activating the AKT signaling
pathway [36] and to increase tumor angiogenesis by increasing the
expression of VEGF [37]. To be consistent with these notions, we
found that an apoptotic index (Bax) was not statistically different in
different ovarian tissues, but the levels of an anti-apoptotic index
(Bcl2), a proliferate index (PCNA), and an angiogenesis index
(VEGF) were all elevated in cancerous tissues compared to those in
normal ovarian tissues and cystadenomas. The metastatic lesions
had the highest levels of a key signaling index in the survival
pathway, activated AKT, such as phospho-AKT (S473). From these
results, we suggest that the elevated expression of huMETCAM/
MUC18 protein may affect many downstream effectors, such as
elevated anti-apoptotic activity, proliferative ability, angiogenesis,
and the activation of signaling in cell survival pathways, which
contributes signiﬁcantly to the progression of clinical ovarian
cancer [34e39]. The results are also consistent with the published
results that expression of PCNA [39], activation of AKT signaling
[36], and expression of VEGF [37] are increased in ovarian cancers.
Taken together, the overexpression of huMETCAM/MUC18 in
ovarian cancer tissues may indicate its role in promoting tumori-
genesis and in initiating the metastasis of human ovarian cancer
cells via these mechanisms.Conclusion
METCAM/MUC18 was overly expressed in ovarian carcinomas
and ovarian metastatic lesions, but not in normal ovarian tissues
and cystadenomas. This correlation of higher levels of huMETCAM/
MUC18 expression in the ovarian cancers may be used as a diag-
nostic marker to differentiate ovarian cancer from benign cyata-
denomas. Our ﬁndings may also be used for the prediction of the
malignant potential of epithelial ovarian cancer; however, this does
not mean that METCAM/MUC18 plays a direct role in the malignant
progression of human ovarian cancer cells and we do not suggest
that METCAM/MUC18 plays a role in the malignant progression of
cystadenomas to ovarian cancers. In summary, our ﬁndings are
consistent with the observations in a recent report [40], which
suggested that METCAM/MUC18 may be a marker of poor prog-
nosis in epithelial ovarian cancer [40]; in addition we also studied
possible pathways involved in the malignant progression of this
cancer.
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